UBS AM’s Lexicon Pharmaceuticals LXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
|
|||||
|
2024
Q4 | $261K | Buy |
|
|||||
|
2024
Q3 | $189K | Buy |
|
|||||
|
2023
Q4 | – | Sell |
|
|||||
|
2023
Q3 | $150K | Hold |
|
|||||
|
2023
Q2 | $335K | Hold |
|
|||||
|
2023
Q1 | $335K | Buy |
|
|||||
|
2022
Q4 | $227K | Hold |
|
|||||
|
2022
Q3 | $286K | Sell |
|
|||||
|
2022
Q2 | $327K | Buy |
|
|||||
|
2022
Q1 | $175K | Hold |
|
|||||
|
2021
Q4 | $330K | Hold |
|
|||||
|
2021
Q3 | $403K | Buy |
|
|||||
|
2021
Q2 | $351K | Buy |
|
|||||
|
2020
Q2 | – | Sell |
|
|||||
|
2020
Q1 | $94.3K | Sell |
|
|||||
|
2019
Q4 | $4.61M | Sell |
|
|||||
|
2019
Q3 | $3.37M | Buy |
|
|||||
|
2019
Q2 | $7.01M | Hold |
|
|||||
|
2019
Q1 | $6.2M | Sell |
|
|||||
|
2018
Q4 | $19.5M | Sell |
|
|||||
|
2018
Q3 | $40.6M | Sell |
|
|||||
|
2018
Q2 | $47.7M | Sell |
|
|||||
|
2018
Q1 | $34.4M | Sell |
|
|||||
|
2017
Q4 | $41.1M | Buy |
|
|||||
|
2017
Q3 | $44M | Sell |
|
|||||
|
2017
Q2 | $62.7M | Sell |
|
|||||
|
2017
Q1 | $58.6M | Sell |
|
|||||
|
2016
Q4 | $57M | Sell |
|
|||||
|
2016
Q3 | $86.6M | Sell |
|
|||||
|
2016
Q2 | $94.3M | Sell |
|
|||||
|
2016
Q1 | $86.3M | Sell |
|
|||||
|
2015
Q4 | $113M | Buy |
|
|||||
|
2015
Q3 | $90.1M | Buy |
|
|||||
|
2015
Q2 | $52.1M | Buy |
|
|||||
|
2015
Q1 | $36.2M | Buy |
|
|||||
|
2014
Q4 | $31.3M | Buy |
|
|||||
|
2014
Q3 | $33.1M | Buy |
|
|||||
|
2014
Q2 | $31.4M | Buy |
|
|||||
|
2014
Q1 | $32.9M | Buy |
|
|||||
|
2013
Q4 | $32.1M | Buy |
|
|||||
|
2013
Q3 | $33.4M | Buy |
|
|||||
|
2013
Q2 | $19.8M | Buy |
|